Alltrna focuses on developing tRNA therapeutics to treat diseases caused by nonsense mutations. It decodes transfer RNA biology to regulate protein synthesis and restore full-length proteins that were truncated by stop codons. How it works: engineered tRNAs read premature stop codons and insert the correct amino acids during protein synthesis, enabling cells to produce full-length proteins despite genetic mutations. Differentiation: Unlike many biotech approaches, Alltrna centers on manipulating tRNA to fix the protein production step at its source. It positions itself as the first company to exploit tRNA biology for therapeutics, aiming to address thousands of diseases sharing the same nonsense mutation across patients. Goal: Create tRNA-based treatments that cure or alleviate diseases caused by nonsense mutations by re-establishing normal protein production in affected cells.
Company Size
11-50
Company Stage
Series B
Total Funding
$159M
Headquarters
Cambridge, Massachusetts
Founded
2018
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?